We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Targeting strategies in the treatment of fumarate hydratase deficient renal cell carcinoma.
- Authors
Lindner, Andrea Katharina; Tulchiner, Gennadi; Seeber, Andreas; Siska, Peter J.; Thurnher, Martin; Pichler, Renate
- Abstract
Fumarate hydratase (FH) - deficient renal cell carcinoma (FHdRCC) is a rare aggressive subtype of RCC caused by a germline or sporadic loss-of-function mutation in the FH gene. Here, we summarize how FH deficiency results in the accumulation of fumarate, which in turn leads to activation of hypoxiainducible factor (HIF) through inhibition of prolyl hydroxylases. HIF promotes tumorigenesis by orchestrating a metabolic switch to glycolysis even under normoxia, a phenomenon well-known as the Warburg effect. HIF activates the transcription of many genes, including vascular endothelial growth factor (VEGF). Crosstalk between HIF and epidermal growth factor receptor (EGFR) has also been described as a tumor-promoting mechanism. In this review we discuss therapeutic options for FHdRCC with a focus on anti-angiogenesis and EGFR-blockade. We also address potential targets that arise within the metabolic escape routes taken by FH-deficient cells for cell growth and survival.
- Subjects
RENAL cell carcinoma; EPIDERMAL growth factor receptors; VASCULAR endothelial growth factors; MERKEL cell carcinoma
- Publication
Frontiers in Oncology, 2022, Vol 12, p1
- ISSN
2234-943X
- Publication type
Article
- DOI
10.3389/fonc.2022.906014